antibody

Recombinant Anti p53 scFv

MBS140082

0.01 mg

205 USD

recombinant

Escherichia coli

nonconjugated

Antibody

Recombinant Anti p53 scFv

p53 scFv

p53 antibody; p53 scFv Recombinant Antibody; LFS1; TRP53; TP53; p53

cellular tumor antigen p53 isoform a; Cellular tumor antigen p53; cellular tumor antigen p53; antigen NY-CO-13; mutant tumor protein 53; p53 tumor suppressor; phosphoprotein p53; transformation-related protein 53; tumor protein p53; Antigen NY-CO-13; Phosphoprotein p53; Tumor suppressor p53

p53

TP53; TP53; P53; BCC7; LFS1; TRP53; P53

P53_HUMAN

E Coli

393

Greater than 95.0% as determined by SDS-PAGE.

p53 is supplied in 10mM Tris HCl, pH 8, 100mM NaCl and 50% glycerol. Sterile Filtered clear solution.

Store at 4 degree C if entire vial will be used within 2-4 weeks. Store, frozen at -20 degree C for longer periods of time. Please avoid freeze thaw cycles.

MONOCLONAL/POLYCLONAL ANTIBODIES, MISCELLANEOUS ANTIBODIES; Monoclonal Antibodies

Description: p53 or TP53 is a cell cycle related transcription factor that promotes transcription of genes that induce cell cycle arrest or apoptosis in response to DNA damage or other cell stresses.This tumour suppressor gene is mutated in about half of all human cancers.Recombinant Anti p53 produced in E Coli is a non-glycosylated, polypeptide chain containing a hexahistidine tag and having a molecular weight of 37 kDa.The rAp53 is purified by proprietary chromatographic techniques. Introduction: Tumor protein p53, a nuclear protein, plays an essential role in the regulation of cell cycle, specifically in the transition from G0 to G1. It is found in very low levels in normal cells, however, in a variety of transformed cell lines, it is expressed in high amounts, and believed to contribute to transformation and malignancy. p53 is a DNA-binding protein containing DNA-binding, oligomerization and transcription activation domains. It is postulated to bind as a tetramer to a p53-binding site and activate expression of downstream genes that inhibit growth and/or invasion, and thus function as a tumor suppressor. Mutants of p53 that frequently occur in a number of different human cancers fail to bind the consensus DNA binding site, and hence cause the loss of tumor suppressor activity. Alterations of the TP53 gene occur not only as somatic mutations in human malignancies, but also as germline mutations in some cancer-prone families with Li-Fraumeni syndrome.

120407068

NP_000537.3

NM_000546.5

24,401 Da

AMPK Signaling Pathway 198868!!Activation Of BH3-only Proteins Pathway 105658!!Activation Of NOXA And Translocation To Mitochondria Pathway 105660!!Activation Of PUMA And Translocation To Mitochondria Pathway 105661!!Alzheimers Disease Pathway 672448!!Amyotrophic Lateral Sclerosis (ALS) Pathway 920975!!Amyotrophic Lateral Sclerosis (ALS) Pathway 83099!!Amyotrophic Lateral Sclerosis (ALS) Pathway 511!!Apoptosis Pathway 198797!!Apoptosis Pathway 83060

This gene encodes a tumor suppressor protein containing transcriptional activation, DNA binding, and oligomerization domains. The encoded protein responds to diverse cellular stresses to regulate expression of target genes, thereby inducing cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism. Mutations in this gene are associated with a variety of human cancers, including hereditary cancers such as Li-Fraumeni syndrome. Alternative splicing of this gene and the use of alternate promoters result in multiple transcript variants and isoforms. Additional isoforms have also been shown to result from the use of alternate translation initiation codons (PMIDs: 12032546, 20937277). [provided by RefSeq, Feb 2013]

0.01 mg

205 USD